Information Provided By:
Fly News Breaks for March 21, 2018
SGEN
Mar 21, 2018 | 07:35 EDT
The Adcetris label expansion approved yesterday for frontline Hodgkin lymphoma was expected, Cantor Fitzgerald analyst Mara Goldstein tells investors in a research note. The analyst continues to believe that upside from additional indications is already built into Adcetris' growth rate and the stock's current valuation. She maintains a Neutral rating on Seattle Genetics with a $50 price target.
News For SGEN From the Last 2 Days
There are no results for your query SGEN